5 papers about lung cancer suggested by Stephen Liu
Stephen Liu, Head of Developmental Therapeutics at Georgetown Lombardi Comprehensive Cancer Center, shared a few must-reads papers on X:
1. Randomized trial of anetumab ravtansine and pembrolizumab compared to pembrolizumab for mesothelioma
Authors: Aaron Mansfield et al.
Authors: Jyoti Malhotra, Alberto Chiappori, Naomi Fujioka, Nasser Hanna, Lawrence Feldman, Malini Patel, Dirk Moore, Chunxia Chen, Salma Jabbour
Authors: Min Hee Hong, Yoon Ji Choi, Hee Kyung Ahn
4. Five-year follow-up of neoadjuvant PD-1 inhibitor (sintilimab) in non-small cell lung cancer
Authors: Bolun Zhou et al.
Authors: Peter Grimison et al.
Follow Stephen Liu on X for more such content.
Stephen Liu is an Associate Professor of Medicine at Georgetown University, where he holds the positions of Director of Thoracic Oncology and Head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center.
As a board-certified medical oncologist specializing in lung cancer and drug development, Dr. Liu is known for his expertise in advanced thoracic malignancies. His research focuses on novel therapeutic agents and innovative combinations to improve treatment outcomes for patients with lung cancer.
Dr. Liu has received multiple teaching awards and actively engages in post-graduate education initiatives. Furthermore, he co-hosts the official podcast of the International Association for the Study of Lung Cancer (IASLC), “Lung Cancer Considered”.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023